Literature DB >> 32628244

Developing a SARS-CoV-2 Vaccine at Warp Speed.

Kevin P O'Callaghan1, Allison M Blatz1, Paul A Offit1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32628244     DOI： 10.1001/jama.2020.12190

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  24 in total

1.  Primary Care's Historic Role in Vaccination and Potential Role in COVID-19 Immunization Programs.

Authors:  Elizabeth Wilkinson; Anuradha Jetty; Stephen Petterson; Yalda Jabbarpour; John M Westfall
Journal:  Ann Fam Med       Date:  2021-03-11       Impact factor: 5.166

2.  Health Communication and Decision Making about Vaccine Clinical Trials during a Pandemic.

Authors:  Aisha T Langford
Journal:  J Health Commun       Date:  2020-10-02

3.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination.

Authors:  Nicola P Klein; Ned Lewis; Kristin Goddard; Bruce Fireman; Ousseny Zerbo; Kayla E Hanson; James G Donahue; Elyse O Kharbanda; Allison Naleway; Jennifer Clark Nelson; Stan Xu; W Katherine Yih; Jason M Glanz; Joshua T B Williams; Simon J Hambidge; Bruno J Lewin; Tom T Shimabukuro; Frank DeStefano; Eric S Weintraub
Journal:  JAMA       Date:  2021-10-12       Impact factor: 56.272

Review 4.  COVID-19: FAQs in Pediatric Cardiac Surgery-A Sequel.

Authors:  Emily Levy; Jennifer Blumenthal; Kathleen Chiotos; Elizabeth H Stephens; Joseph A Dearani
Journal:  World J Pediatr Congenit Heart Surg       Date:  2020-09-10

5.  The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.

Authors:  Justin R Ortiz; Joanie Robertson; Jui-Shan Hsu; Stephen L Yu; Amanda J Driscoll; Sarah R Williams; Wilbur H Chen; Meagan C Fitzpatrick; Samba Sow; Robin J Biellik; Kathleen M Neuzil
Journal:  Vaccine       Date:  2021-02-19       Impact factor: 3.641

6.  US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.

Authors:  Rafael Dal-Ré
Journal:  Vaccine       Date:  2021-01-20       Impact factor: 3.641

7.  A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.

Authors:  Leonidas Stamatatos; Julie Czartoski; Yu-Hsin Wan; Leah J Homad; Vanessa Rubin; Hayley Glantz; Moni Neradilek; Emilie Seydoux; Madeleine F Jennewein; Anna J MacCamy; Junli Feng; Gregory Mize; Stephen C De Rosa; Andrés Finzi; Maria P Lemos; Kristen W Cohen; Zoe Moodie; M Juliana McElrath; Andrew T McGuire
Journal:  medRxiv       Date:  2021-03-10

Review 8.  SARS-CoV-2: vaccines in the pandemic era.

Authors:  Dan-Dan Li; Qi-Han Li
Journal:  Mil Med Res       Date:  2021-01-06

9.  Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.

Authors:  Linling He; Xiaohe Lin; Ying Wang; Ciril Abraham; Cindy Sou; Timothy Ngo; Yi Zhang; Ian A Wilson; Jiang Zhu
Journal:  Sci Adv       Date:  2021-03-19       Impact factor: 14.136

10.  Socialized and traumatized: Pharmacists, underserved patients, and the COVID-19 vaccine.

Authors:  Angela C Riley; Hope Campbell; Lakesha Butler; Cheryl Wisseh; Nkem P Nonyel; Trishia E Shaw
Journal:  J Am Pharm Assoc (2003)       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.